{"id":"https://openalex.org/W2994100764","doi":"https://doi.org/10.1158/1535-7163.targ-19-c030","title":"Abstract C030: A new low potency DNA guanine monoalkylating ADC payload with enhanced i n vivo tolerability","display_name":"Abstract C030: A new low potency DNA guanine monoalkylating ADC payload with enhanced i n vivo tolerability","publication_year":2019,"publication_date":"2019-12-01","ids":{"openalex":"https://openalex.org/W2994100764","doi":"https://doi.org/10.1158/1535-7163.targ-19-c030","mag":"2994100764"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.targ-19-c030","doi":"https://doi.org/10.1158/1535-7163.targ-19-c030","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-19-c030","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2994100764"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059307227","display_name":"Nicolas Veillard","orcid":"https://orcid.org/0009-0002-7536-2519","observed_orcids":["https://orcid.org/0009-0002-7536-2519"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nicolas Veillard","raw_affiliation_strings":["Femtogenix, Harpenden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Femtogenix, Harpenden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5046572091","display_name":"Paolo Andriollo","orcid":"https://orcid.org/0009-0006-3754-6877","observed_orcids":["https://orcid.org/0009-0006-3754-6877"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Andriollo","raw_affiliation_strings":["Femtogenix, Harpenden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Femtogenix, Harpenden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075040264","display_name":"Francesco Cascio","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Francesco Cascio","raw_affiliation_strings":["Femtogenix, Harpenden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Femtogenix, Harpenden","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103413662","display_name":"Paul J. Jackson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul J. M. Jackson","raw_affiliation_strings":["Femtogenix, Harpenden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Femtogenix, Harpenden","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015974843","display_name":"David E. Thurston","orcid":"https://orcid.org/0000-0001-8032-7203","observed_orcids":["https://orcid.org/0000-0001-8032-7203","https://orcid.org/0000-0001-7845-0704"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"David E. Thurston","raw_affiliation_strings":["Femtogenix, Harpenden"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Femtogenix, Harpenden","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"18","issue":"12_Supplement","first_page":"C030","last_page":"C030"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T13105","display_name":"Synthesis and pharmacology of benzodiazepine derivatives","score":0.9872999787330627,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.004999999888241291,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12477","display_name":"Toxin Mechanisms and Immunotoxins","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9919999837875366},{"id":"https://openalex.org/keywords/therapeutic-window","display_name":"therapeutic window","score":0.7300000190734863},{"id":"https://openalex.org/keywords/hydrophobicity","display_name":"hydrophobicity","score":0.796999990940094},{"id":"https://openalex.org/keywords/cetuximab","display_name":"cetuximab","score":0.7300000190734863},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.7940000295639038},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.7490000128746033}],"concepts":[{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.7802987098693848},{"id":"https://openalex.org/C57992300","wikidata":"https://www.wikidata.org/wiki/Q2066956","display_name":"Potency","level":3,"score":0.7601883411407471},{"id":"https://openalex.org/C552990157","wikidata":"https://www.wikidata.org/wiki/Q7430","display_name":"DNA","level":2,"score":0.6032541394233704},{"id":"https://openalex.org/C2778301229","wikidata":"https://www.wikidata.org/wiki/Q169313","display_name":"Guanine","level":4,"score":0.5393462181091309},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4831647276878357},{"id":"https://openalex.org/C109316439","wikidata":"https://www.wikidata.org/wiki/Q246181","display_name":"Cytotoxicity","level":3,"score":0.4809674322605133},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.41385698318481445},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.3898364007472992},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.3671366572380066},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.32251912355422974},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2567024230957031},{"id":"https://openalex.org/C512185932","wikidata":"https://www.wikidata.org/wiki/Q28745","display_name":"Nucleotide","level":3,"score":0.10431396961212158},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.09763461351394653},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.targ-19-c030","doi":"https://doi.org/10.1158/1535-7163.targ-19-c030","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.targ-19-c030","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4283168722","https://openalex.org/W2885435112","https://openalex.org/W2956010095","https://openalex.org/W4282964559","https://openalex.org/W2958606784","https://openalex.org/W4282966081","https://openalex.org/W4288535293","https://openalex.org/W2085068813","https://openalex.org/W4408311480","https://openalex.org/W2341585353"],"abstract_inverted_index":{"Abstract":[0],"Although":[1],"five":[2],"Antibody-Drug":[3],"Conjugates":[4],"(ADCs)":[5],"have":[6,39,46,154,231],"been":[7,232,276],"approved":[8],"and":[9,26,37,49,73,138,262,295,309,370],"over":[10],"eighty":[11],"others":[12],"are":[13,83],"in":[14,58,66,123,125,129,140,146,165,176,184,206,217,222,254,306,327,356],"development,":[15],"the":[16,34,126,150,177,185,215,242,290,304,312,363],"majority":[17],"contain":[18,95],"payloads":[19,32,61,212],"belonging":[20],"to":[21,102,105,168,196,209,241,258,300],"two":[22],"classes:":[23],"tubulin":[24],"inhibitors":[25],"DNA":[27,89,107,160,170,349],"interactive":[28],"agents.":[29,172],"Most":[30],"DNA-interactive":[31,211,260],"(e.g.,":[33,109,181],"PBD":[35],"dimers":[36],"IGNs)":[38],"potent":[40,224],"cytotoxicity":[41],"but":[42,69,192],"ADCs":[43,230,251,313],"containing":[44],"them":[45,104],"high":[47,116],"hydrophobicity":[48,72,287],"a":[50,74,84,96,130,157,223,236,263,323],"narrow":[51],"therapeutic":[52],"window.":[53],"Thus,":[54],"there":[55],"is":[56,121,135,174,193],"interest":[57],"developing":[59],"novel":[60],"which":[62,94],"benefit":[63],"from":[64],"similar":[65],"vivo":[67,141,166,255,307,357],"efficacy":[68,256,308],"possess":[70],"lower":[71,158],"substantially":[75,163,227,264],"wider":[76],"Therapeutic":[77],"Window":[78],"(TW).":[79],"The":[80,114,204,250,285],"pyridinobenzodiazepines":[81],"(PDDs)":[82],"new":[85,325,346],"class":[86],"of":[87,133,219,239,248,289,298,311,362],"sequence-selective,":[88],"guanine":[90,350],"monoalkylating":[91,351],"ADC":[92,147,225,328,352],"payload":[93,119,321,353],"polyheterocyclic":[97],"chain":[98],"with":[99,162,226,246,303,354],"sufficient":[100],"span":[101],"guide":[103],"specific":[106],"sequences":[108],"transcription":[110],"factor":[111],"binding":[112],"sites).":[113],"lead":[115],"potency":[117,142,159,218,292,319,348],"PDD":[118,151],"(FGX2-62)":[120],"active":[122,175],"vitro":[124],"picomolar":[127],"range":[128,180],"wide":[131],"panel":[132],"cell-lines,":[134],"easily":[136],"conjugated":[137],"has":[139,273],"at":[143,200,278],"sub-mg/kg":[144],"levels":[145],"form.":[148],"Within":[149],"platform,":[152],"we":[153],"now":[155],"developed":[156],"monoalkylator":[161],"superior":[164],"properties":[167],"other":[169,210,259],"alkylating":[171],"FGX20-75":[173,240],"low":[178,291,318,347],"nanomolar":[179],"2.1":[182],"nM":[183],"gastric":[186],"cell-line":[187],"SW48,":[188],"72":[189],"hour":[190],"incubation),":[191],"sufficiently":[194],"hydrophilic":[195],"allow":[197],"efficient":[198],"conjugation":[199,299],"DARs":[201],">":[202],"4.":[203],"increase":[205],"loading":[207],"compared":[208,257],"compensates":[213],"for":[214],"drop":[216],"FGX20-75,":[220],"resulting":[221],"increased":[228,265],"tolerability.":[229],"generated":[233],"by":[234],"conjugating":[235],"maleimide-linked":[237],"analogue":[238],"EGFR-targeting":[243],"antibody":[244],"Cetuximab":[245],"DAR":[247],"4.2.":[249],"exhibit":[252],"significant":[253,305],"payloads,":[261],"tolerability":[266,310,358],"profile.":[267],"A":[268,345],"maximum":[269],"tolerated":[270],"dose":[271],"(MTD)":[272],"not":[274],"yet":[275],"reached":[277],"35":[279],"mg/kg":[280],"(single":[281],"dose,":[282],"CD1":[283],"mice).":[284],"favourable":[286],"profile":[288],"alkylator":[293],"(FGX20-75)":[294],"its":[296],"ease":[297],"antibodies,":[301],"along":[302],"produced,":[314],"suggest":[315],"that":[316],"this":[317],"DNA-alkylating":[320],"represents":[322],"promising":[324],"approach":[326],"development.":[329],"Citation":[330],"Format:":[331],"Nicolas":[332],"Veillard,":[333],"Paolo":[334],"Andriollo,":[335],"Francesco":[336],"Cascio,":[337],"Paul":[338],"J.":[339],"M.":[340],"Jackson,":[341],"David":[342],"E.":[343],"Thurston.":[344],"enhanced":[355],"[abstract].":[359],"In:":[360],"Proceedings":[361],"AACR-NCI-EORTC":[364],"International":[365],"Conference":[366],"on":[367],"Molecular":[368],"Targets":[369],"Cancer":[371,382],"Therapeutics;":[372],"2019":[373],"Oct":[374],"26-30;":[375],"Boston,":[376],"MA.":[377],"Philadelphia":[378],"(PA):":[379],"AACR;":[380],"Mol":[381],"Ther":[383],"2019;18(12":[384],"Suppl):Abstract":[385],"nr":[386],"C030.":[387],"doi:10.1158/1535-7163.TARG-19-C030":[388]},"counts_by_year":[],"updated_date":"2026-11-05T12:25:35.769452","created_date":"2019-12-13T00:00:00"}